Recent Posts

Pages: [1] 2 3 ... 10
GENERAL DISCUSSION - RESEARCH, NEWS / Highlights of annual AAN meeting (from NMSS)
« Last post by agate on May 20, 2019, 06:59:43 am »
The National MS Society's article highlighting the annual AAN meeting held in Philadelphia, May 4-10, 2019:,-Advances-in-Stopping-Progre
ANNOUNCEMENTS / MS Speaks now going into its 14th year
« Last post by agate on May 20, 2019, 06:20:57 am »
Just a pat on the back for MS Speaks here because it's been steadily present online for over 13 years now.

NEWS / Body Mass Index (BMI) flawed?
« Last post by agate on May 19, 2019, 08:47:02 pm »
A couple of studies in which the results challenge the BMI as a health index have been highlighted recently (May 19, 2019) by ScienceAlert even though the studies were done in 2016:

We may be able to get away with more excess pounds than we thought we could.

« Last post by agate on May 16, 2019, 02:58:03 pm »

This article from MedPage Today (May 16, 2019) discusses the relative risk of PML that is involved in the different MS drugs--"Clinical Challenges: PML in Multiple Sclerosis":
Neurofilament light chains received quite a bit of attention at the annual AAN conference for 2019 (Philadelphia, May 4-10). They're mentioned in this article from Multiple Sclerosis News Today (May 15, 2019) entitled "Biogen Offers Update on Development Plans for MS Therapies." The Biogen spokesperson is announcing another new MS drug, Vumerity, which is up for FDA review:
The concern about stroke risk has prompted the European Medicines Agency to restrict the use of alemtuzumab pending review. From The Lancet (April 27, 2019), "Alemtuzumab to be restricted pending review, says EMA":
GENERAL DISCUSSION - RESEARCH, NEWS / Large clinical trials going unreported
« Last post by agate on May 14, 2019, 04:21:03 pm »
From the "Summary and Comment" section of NEJM Journal Watch (May 14, 2019), "Many Large Clinical Trials Have Gone Missing":
From JAMA Neurology (May 13, 2019), "Clinical outcomes of escalation vs. early intensive disease-modifying therapy in patients with multiple sclerosis":
A whopping 43% of the patients indexed in the US (75,473 in all) weren't on any MS drugs.

Presented at the annual AAN conference (May 4-10, 2019), "Untreated Patients with Multiple Sclerosis: Prevalence and Characteristics in Denmark and in the United States":

Presented at the annual AAN conference, "Spontaneous Intracerebral Hemorrhage During Administration of Alemtuzumab for Multiple Sclerosis: A Case Series":

Pages: [1] 2 3 ... 10